Form 4: Astera Labs CFO Michael Tate Sells 100,000 Shares Under 10b5-1 Trading Plan

Michael Tate, CFO of Astera Labs, sold 100,000 shares of common stock on October 9, 2024, at a weighted average price of $62.0336, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Summary

• On October 9, 2024, Michael Tate, the Chief Financial Officer of Astera Labs, sold 100,000 shares of the company's common stock.
• The sale was executed at a weighted average price of $62.0336 per share.
• The transactions occurred automatically under a Rule 10b5-1 trading plan adopted on May 30, 2024.
• Following the transaction, Tate directly owns 293,128 shares and indirectly owns 1,762,888 shares through the Tate Trust.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing an insider stock sale. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure of insider trading activity. It's common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. The impact on the stock price is usually minimal unless the sale is unusually large.

Stakeholder Impact

• The stock sale by a key executive could be perceived negatively by some shareholders, although the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates